Amicus Therapeutics: Offering Therapies to Orphan and Rare Diseases
Amicus Therapeutics is an American biopharmaceutical company located in Cranbury, New Jersey. In 2007, Amicus Therapeutic went public under the NASDAQ trading symbol FOLD. Before Amicus went public, several investment capital corporations such as Canaan Partners, New Enterprise Associates, and Radius Ventures funded it.
Amicus Therapeutics focuses on orphan and rare diseases such as Lysosomal Storage Disorder (LSD), genomic connective tissue disorder, Pompe, and Fabry disease. The company is at the pole position of innovative treatments to treat these devastating diseases. The company’s primary product, Migalastat, is a modified medicine in its advanced stages of development to treat patients suffering from Fabry disease based on their genomic diagnosis. Another product candidate at its late-stage advancement is the SD-101, which should handle rare genomic connective tissue disorder, Epidermolysis Bullosa (EB). Visit finance.yahoo.com to know more about Amicus Therapeutics.
Amicus Therapeutics is a science and business oriented company, which is dedicated to delivering meaningful benefits to patients. The company has advanced platform technologies and the product pipeline that position it at the lead for developing treatments to address critical unmet desires for these shattering diseases.
Amicus is leveraging its inventive technology platforms to advance therapies for genomic diseases by precisely targeting modified proteins. The experts exploring these techniques are enthusiastic to discovering improved cures for patients anguishing from these rare ailments. Their desire fuels advancement and enables Amicus Therapeutics to deliver essential benefits.
Amicus collaborates with individual patients, patient organizations, caretakers, and health practitioners to ensure support is offered to the rare disease community. Visit Google Finance to know more about Amicus Therapeutics.